Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, or their legally authorized representative, must voluntarily provide written IRB-approved informed consent.~* Males and females, 18 years of age or older at the time of enrollment.~* Patients must meet the diagnostic criteria for HPS (at least 5 of the following): fever, splenomegaly, cytopenia involving ≥2 cell lines (Hemoglobin \<9 g/dL; platelets \<100,000/μL; absolute neutrophil count \<1000/μL), hypertriglyceridemia or hypofibrinogenemia, tissue demonstration of hemophagocytosis, low or absent NK (Natural Killer) cell activity, serum ferritin ≥3000 ug/L, soluble IL-2 receptor (CD25) \>2400 U/mL.~* In the investigator's opinion, the patient has the ability to participate fully in the study, and comply with all its requirements.~Exclusion Criteria:~* CNS (Central Nervous System) involvement~* Malabsorption~* Known secondary HPS (Hemophagocytic Syndrome) that is otherwise treatable (e.g. non-Hodgkin's lymphoma).~* Pregnant or lactating female: all females of child-bearing potential must have a negative serum pregnancy test within 7 days of treatment; lactating females must discontinue breast feeding.~* Estimated creatinine clearance \<15mL/min~* Has received any prior systemic therapy, excluding corticosteroids, within 7 days (or 5 half-lives) of treatment.~* No active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in situ. Patients with a prior history of malignancy are eligible if their malignancy has been definitely treated or is in remission and does not require ongoing adjuvant or cancer-directed therapies.~* Active hepatitis B or hepatitis C or known HIV infection~* Known (and biopsy-confirmed) liver cirrhosis; or, a reported history of liver cirrhosis with a Model for End-stage Liver Disease (MELD) score \>20.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): Ruxolitinib 15 mg by mouth twice daily.~For patients unable to ingest tablets, ruxolitinib suspended in water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube.

Based on this trial design, predict the completion outcome and termination type (if applicable).